



# Divi's Laboratories Limited

November 06, 2021

To  
The Secretary  
**National Stock Exchange of India Limited**  
Exchange Plaza,  
Bandra-Kurla Complex, Bandra (East)  
**MUMBAI – 400 051**

To  
The Secretary  
**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street  
**MUMBAI – 400 001**

**Stock Code: DIVISLAB**

**Stock Code: 532488**

Dear Sir/ Madam,

**Sub: Out-come of Board Meeting - Unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended September 30, 2021**

**Ref: Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015**

Further to our intimation dated October 28, 2021, we would like to inform that the Board of Directors of the Company at its meeting held on November 06, 2021 has, inter alia, approved the Unaudited Financial Results for the quarter and half year ended September 30, 2021.

In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we enclose herewith the following:

1. Unaudited standalone financial results for the quarter and half year ended September 30, 2021 along with Limited Review Report of the Statutory Auditors thereon.
2. Unaudited consolidated financial results for quarter and half year ended September 30, 2021 along with Limited Review Report of the Statutory Auditors thereon.
3. Press Release on the said Financial Results of the Company.

The Board meeting commenced at 10.00 Hrs and concluded at 11.40 Hrs.

This is for your information and records.

Thanking You,  
Yours faithfully,  
**For Divi's Laboratories Limited**

  
**M. Satish Choudhury**  
**Company Secretary & Compliance Officer**



**“An ISO-9001, ISO-14001 and OHSAS-18001 Triple certified company”**

**Regd. Off. :** Divi Towers, 1-72/23(P)/DIVIS/303, Cyber Hills, Gachibowli, Hyderabad - 500 032, Telangana, INDIA.

Tel : 91-40-2378 6300, Fax : 91-40-2378 6460, CIN : L24110TG1990PLC011854

E-mail : mail@divislabs.com, Website : www.divislabs.com

**DIVI'S LABORATORIES LIMITED**

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS  
FOR THE QUARTER AND HALF YEAR ENDED 30<sup>TH</sup> SEPTEMBER 2021

(Rs. in lakhs)

S. No.	Particulars	Quarter ended			Half Year ended		Year ended
		30.09.2021	30.06.2021	30.09.2020	30.09.2021	30.09.2020	31.03.2021
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
<b>1</b>	<b>Income:</b>						
	Revenue from operations	<b>196786</b>	195016	171378	<b>391802</b>	342374	679861
	Other income	<b>1911</b>	3555	1364	<b>4775</b>	2616	6253
	<b>Total Income</b>	<b>198697</b>	198571	172742	<b>396577</b>	344990	686114
<b>2</b>	<b>Expenses</b>						
	a) Cost of materials consumed	<b>86253</b>	76375	53561	<b>162628</b>	99510	236550
	b) Purchases of stock-in-trade	-	-	-	-	-	-
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	<b>(21185)</b>	(11953)	3065	<b>(33138)</b>	20784	(10000)
	d) Employee benefits expense	<b>21908</b>	21626	18871	<b>43534</b>	36906	80868
	e) Depreciation and amortization expense	<b>7709</b>	7301	6089	<b>15010</b>	11686	25465
	f) Finance costs	<b>17</b>	24	11	<b>41</b>	29	69
	g) Other expenses	<b>27951</b>	23821	22642	<b>51081</b>	41502	90375
	<b>Total expenses</b>	<b>122653</b>	117194	104239	<b>239156</b>	210417	423327
<b>3</b>	<b>Profit before exceptional Items and tax (1-2)</b>	<b>76044</b>	81377	68503	<b>157421</b>	134573	262787
<b>4</b>	Exceptional items	-	-	-	-	-	-
<b>5</b>	<b>Profit before Tax (3-4)</b>	<b>76044</b>	81377	68503	<b>157421</b>	134573	262787
<b>6</b>	Tax expense						
	a) Current tax	<b>13383</b>	23948	14441	<b>37331</b>	33089	60905
	b) Deferred tax	<b>2022</b>	2232	2732	<b>4254</b>	929	6410
	<b>Total tax expense</b>	<b>15405</b>	26180	17173	<b>41585</b>	34018	67315
<b>7</b>	<b>Profit for the period (5-6)</b>	<b>60639</b>	55197	51330	<b>115836</b>	100555	195472
<b>8</b>	<b>Other Comprehensive Income:</b>						
	Items that will not be reclassified to Profit or Loss:						
	Gain/(Loss) Remeasurement of post-employment benefit obligation	<b>6</b>	<b>6</b>	(38)	<b>12</b>	(76)	25
	Income tax relating to the above	<b>(2)</b>	(2)	14	<b>(4)</b>	27	(9)
	Total other comprehensive income	<b>4</b>	<b>4</b>	(24)	<b>8</b>	(49)	16
<b>9</b>	<b>Total comprehensive income for the period (7+8)</b>	<b>60643</b>	55201	51306	<b>115844</b>	100506	195488
<b>10</b>	Paid-up Equity Share Capital (Face Value: Rs.2/- per share)	<b>5309</b>	5309	5309	<b>5309</b>	5309	5309
<b>11</b>	Other Equity excluding revaluation reserve						921848
<b>12</b>	Earnings per Share of Rs.2/- each (not annualized)						
	a) Basic (Rs.)	<b>22.84</b>	20.79	19.34	<b>43.63</b>	37.88	73.63
	b) Diluted (Rs.)	<b>22.84</b>	20.79	19.34	<b>43.63</b>	37.88	73.63






**DIVI'S LABORATORIES LIMITED**

**STATEMENT OF STANDALONE UNAUDITED ASSETS AND LIABILITIES AS AT 30<sup>TH</sup> SEPTEMBER 2021**  
(Rs. in lakhs)

S. No.	Particulars	As At	
		30.09.2021	31.03.2021
		Unaudited	Audited
<b>A</b>	<b>ASSETS</b>		
<b>1</b>	<b>Non-current assets</b>		
	Property, plant and equipment	410677	369406
	Capital work-in-progress	44022	71062
	Intangible assets	677	495
	Financial assets		
	a) Investments	737	737
	b) Other financial assets	5271	5661
	Income tax assets (net)	6151	6860
	Other non-current assets	7410	5625
	<b>Sub-total: Non-current assets</b>	<b>474945</b>	<b>459846</b>
<b>2</b>	<b>Current assets</b>		
	Inventories	253384	204270
	Financial assets		
	a) Trade receivables	195494	174556
	b) Cash and cash equivalents	175060	201630
	c) Bank balances other than (b) above	11697	12571
	d) Other financial assets	822	947
	Income tax assets (net)	3427	3427
	Other current assets	22514	15130
	<b>Sub-total: Current assets</b>	<b>662398</b>	<b>612531</b>
	<b>TOTAL ASSETS</b>	<b>1137343</b>	<b>1072377</b>
<b>B</b>	<b>EQUITY AND LIABILITIES</b>		
<b>1</b>	<b>Equity:</b>		
	Share Capital	5309	5309
	Other Equity	984598	921848
	<b>Sub-total: Equity</b>	<b>989907</b>	<b>927157</b>
<b>2</b>	<b>Liabilities:</b>		
	<b>Non-current liabilities</b>		
	Provisions	3062	2525
	Deferred tax liabilities (net)	38060	33806
	<b>Sub-total: Non-current liabilities</b>	<b>41122</b>	<b>36331</b>
<b>3</b>	<b>Current Liabilities</b>		
	Financial liabilities		
	a) Borrowings	7	35
	b) Trade payables		
	Dues to micro and small enterprises	1176	3248
	Dues to creditors other than micro and small enterprises	79404	71630
	c) Other financial liabilities	5784	7824
	Other current liabilities	18302	25901
	Current tax liabilities (net)	1390	-
	Provisions	251	251
	<b>Sub-total: Current liabilities</b>	<b>106314</b>	<b>108889</b>
	<b>Total Liabilities</b>	<b>147436</b>	<b>145220</b>
	<b>TOTAL EQUITY AND LIABILITIES</b>	<b>1137343</b>	<b>1072377</b>



**DIVI'S LABORATORIES LIMITED**

**STATEMENT OF STANDALONE UNAUDITED CASH FLOWS FOR THE HALF YEAR ENDED 30<sup>TH</sup> SEPTEMBER 2021**

**(Rs. in lakhs)**

Particulars	30.09.2021 (Unaudited)	30.09.2020 (Unaudited)	31.03.2021 (Audited)
<b>A. Cash flow from operating activities</b>			
Profit before tax	157421	134573	262787
Adjustments for:			
Depreciation and amortisation expense	15010	11686	25465
Unrealised foreign exchange loss/ (gain)	(233)	105	(1376)
Interest income from financial assets at amortized cost	(3347)	(2274)	(5724)
Net gain on redemption /disposal of investments	-	(265)	(265)
Provision for doubtful debts / (written back) [including write-off]	(135)	(57)	(92)
Finance costs	41	11	69
Loss on disposal / discard of assets	136	(11)	596
Government grants	(4)	(3)	(7)
	<b>168889</b>	<b>143765</b>	<b>281453</b>
<b>Change in operating assets and liabilities</b>			
(Increase) /Decrease in trade receivables	(21421)	(16443)	(21329)
(Increase) /Decrease in inventories	(49114)	17290	(29853)
Increase /(Decrease) in trade payables	5935	(4228)	17078
(Increase) /Decrease in current Loans	-	-	9
(Increase) /Decrease in other non-current assets	(123)	20	(232)
(Increase) /Decrease in non-current financial assets	390	(436)	(2161)
(Increase) /Decrease in other current financial assets	125	(393)	(558)
(Increase) /Decrease in other current assets	(7384)	4563	7075
Increase /(Decrease) in long term employee benefit obligation	549	242	498
Increase /(Decrease) in short term employee benefit obligation	-	(76)	5
Increase/ (Decrease) in other financial liabilities	218	(2903)	(2864)
Increase /(Decrease) in other current liabilities	(6981)	(95)	8880
<b>Cash generated from operations</b>	<b>91083</b>	<b>141306</b>	<b>258001</b>
Income taxes paid including withholding tax and net of refunds	(35236)	(24967)	(63296)
<b>Net cash inflow from operating activities</b>	<b>55847</b>	<b>116339</b>	<b>194705</b>
<b>B. Cash flows from investing activities</b>			
Payments for property, plant and equipment	(33454)	(37418)	(90998)
Proceeds from sale of property, plant and equipment	-	14	15
Payments for purchase of Investments	-	-	(10000)
Proceeds out of sale of Investments	-	97400	107400
Interest received	3137	2460	5701
Proceeds from withdrawal of deposits	1471	-	6810
Investment in deposits	(408)	(4460)	(11394)
<b>Net cash inflow / (outflow) from investing activities</b>	<b>(29254)</b>	<b>57996</b>	<b>7534</b>



**DIVI'S LABORATORIES LIMITED**

**STATEMENT OF STANDALONE UNAUDITED CASH FLOWS FOR THE HALF YEAR ENDED 30<sup>TH</sup> SEPTEMBER 2021**  
(Rs. in lakhs)

Particulars	30.09.2021 (Unaudited)	30.09.2020 (Unaudited)	31.03.2021 (Audited)
<b>C. Cash flows from financing activities</b>			
Proceeds/ (Repayment) of working capital loans (net)	(28)	(3340)	(3328)
Finance costs	(41)	(11)	(69)
Dividends paid to company's shareholders	(53094)	--	-
<b>Net cash inflow / (outflow) from financing activities</b>	<b>(53163)</b>	<b>(3351)</b>	<b>(3397)</b>
<b>Net increase / (Decrease) in cash and cash equivalents (A+B+C)</b>	<b>(26570)</b>	<b>170984</b>	<b>198842</b>
Cash and cash equivalents at the beginning of the financial year	201630	2788	2788
<b>Cash and cash equivalents at end of the year/period</b>	<b>175060</b>	<b>173772</b>	<b>201630</b>

**NOTES:**

- The above Statement of standalone unaudited financial results for the quarter and half year ended 30<sup>th</sup> September, 2021, Statement of standalone unaudited assets and liabilities as at 30<sup>th</sup> September, 2021 and Statement of standalone unaudited cash flows for the half year ended 30<sup>th</sup> September, 2021 ('Standalone Statements') are prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under section 133 of the Companies Act 2013 read with the relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. The same were, as reviewed by the Audit Committee, considered and approved by the Board of Directors at its meeting held on 6<sup>th</sup> November, 2021. The same also were subjected to "limited review" by the Auditors of the Company and their report contains no qualification.
- The Company is engaged in the manufacture of Active Pharmaceutical Ingredients, Intermediates and Nutraceutical Ingredients and the same constitutes a single reportable business segment as per Ind AS 108.
- The Company does not have any discontinued operations and the Profit for the period represents the Profits from continuing operations only.
- The Company has not experienced any significant impact on its operations, supply chain and recoverability of carrying amounts of financial and non-financial assets due to COVID 19 pandemic. As the pandemic continues to evolve, the Company will continue to closely monitor for any material changes to future economic conditions.
- Forex gain included in Other Income and Loss included in Other Expenses for the respective periods is as given below:

Rs. in lakhs

	Quarter ended			Half Year ended		Year ended
	30.09.2021	30.06.2021	30.09.2020	30.09.2021	30.09.2020	31.03.2021
<b>Forex gain/(loss)</b>	<b>(691)</b>	1922	(1228)	<b>1231</b>	(693)	(77)

- Figures for the previous year/period have been reclassified/ regrouped wherever necessary to conform to current period's classification.

Place: Hyderabad  
Date: 6<sup>th</sup> November, 2021

For Divi's Laboratories Limited

Dr. Murali K. Divi  
Managing Director




# Price Waterhouse Chartered Accountants LLP

## Review Report

To  
The Board of Directors  
M/s. Divi's Laboratories Limited  
Divis Towers, 1-72/23(P)/303,  
Cyber hills, Gachibowli,  
Hyderabad, 500032

1. We have reviewed the standalone unaudited financial results of Divi's Laboratories Limited (the "Company") for the quarter ended September 30, 2021 and the year to date results for the period April 01, 2021 to September 30, 2021, which are included in the accompanying "Statement of Standalone Unaudited financial results for the quarter and half year ended September 30, 2021", the "Statement of Standalone Unaudited Assets and Liabilities as on September 30, 2021" and the "Statement of Standalone Unaudited Cash Flows for the half-year ended September 30, 2021" (the "Standalone Statement"). The Standalone Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations, 2015"), which has been stamped by us for identification purposes. The Standalone Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Standalone Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Standalone Statement is free of material misstatement.
3. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Standalone Statement has not been prepared in all material respects in accordance with the applicable Accounting Standards prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Price Waterhouse Chartered Accountants LLP  
Firm Registration Number: 012754N/N500016

  
Sunit Kumar Basu  
Partner  
Membership Number 55000  
UDIN: 21055000AAAAKV9123

Place: Hyderabad  
Date: November 06, 2021

Price Waterhouse Chartered Accountants LLP, Unit - 2B, 8th Floor, Octave Block, Block E1, Parcel - 4, Salarpuria Sattva Knowledge City, Raidurg, Hyderabad, Telangana - 500081  
T: +91 (40) 4424 6000, F: +91 (40) 4424 6300

Registered office and Head office: Sucheta Bhawan, 11A Vishnu Digambar Marg, New Delhi 110 002


Price Waterhouse (a Partnership Firm) converted into Price Waterhouse Chartered Accountants LLP (a Limited Liability Partnership with LLP identity no: LLPIN AAC-5001) with effect from July 25, 2014. Post its conversion to Price Waterhouse Chartered Accountants LLP, its ICAI registration number is 012754N/N500016 (ICAI registration number before conversion was 012754N)

**DIVI'S LABORATORIES LIMITED**

**STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS  
FOR THE QUARTER AND HALF YEAR ENDED 30<sup>TH</sup> SEPTEMBER 2021**

(Rs. in lakhs)

S. No	Particulars	Quarter ended			Half Year ended		Year ended
		30.09.2021	30.06.2021	30.09.2020	30.09.2021	30.09.2020	31.03.2021
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
<b>1</b>	<b>Income:</b>						
	Revenue from operations	198751	196064	174930	394815	347977	696940
	Other income	1911	3597	1364	4796	2616	6256
	<b>Total Income</b>	<b>200662</b>	<b>199661</b>	<b>176294</b>	<b>399611</b>	<b>350593</b>	<b>703196</b>
<b>2</b>	<b>Expenses</b>						
	a) Cost of materials consumed	87651	78429	53924	166080	100351	239744
	b) Purchases of stock-in-trade	-	640	25	640	404	531
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(22168)	(14855)	3678	(37023)	20856	(7867)
	d) Employee benefits expense	22398	22080	19318	44478	37708	82576
	e) Depreciation and amortization expense	7735	7326	6113	15061	11733	25559
	f) Finance costs	21	28	16	49	39	87
	g) Other expenses	29063	24565	23871	52916	44055	95962
	<b>Total expenses</b>	<b>124700</b>	<b>118213</b>	<b>106945</b>	<b>242201</b>	<b>215146</b>	<b>436592</b>
<b>3</b>	<b>Profit before exceptional Items and tax (1-2)</b>	<b>75962</b>	<b>81448</b>	<b>69349</b>	<b>157410</b>	<b>135447</b>	<b>266604</b>
<b>4</b>	Exceptional items	-	-	-	-	-	-
<b>5</b>	<b>Profit before Tax (3-4)</b>	<b>75962</b>	<b>81448</b>	<b>69349</b>	<b>157410</b>	<b>135447</b>	<b>266604</b>
<b>6</b>	<b>Tax Expense</b>						
	a) Current tax	13558	24170	14674	37728	33459	61646
	b) Deferred tax	1758	1567	2716	3325	823	6529
	<b>Total tax expense</b>	<b>15316</b>	<b>25737</b>	<b>17390</b>	<b>41053</b>	<b>34282</b>	<b>68175</b>
<b>7</b>	<b>Profit for the period (5-6)</b>	<b>60646</b>	<b>55711</b>	<b>51959</b>	<b>116357</b>	<b>101165</b>	<b>198429</b>
<b>8</b>	Profit for the period attributable to:						
	Shareholders of the Company	60646	55711	51959	116357	101165	198429
	Non-Controlling Interest	-	-	-	-	-	-
<b>9</b>	Other Comprehensive Income:						
	a) Items that will not be reclassified to Profit or Loss:						
	i) Gain/(Loss) on Remeasurement of post-employment benefit obligations	6	6	(38)	12	(76)	25
	ii) Income tax relating to the above	(2)	(2)	14	(4)	27	(9)
	b) Items that will be reclassified to Profit or Loss:						
	i) Exchange differences in translating the financial statements of foreign operations	26	98	206	124	238	22
	ii) Income tax relating to the above	(12)	75	(30)	63	(33)	2
	Total other comprehensive income (a+b)	18	177	152	195	156	40
<b>10</b>	Total other comprehensive income for the period attributable to:						
	Shareholders of the Company	18	177	152	195	156	40
	Non-Controlling Interest	-	-	-	-	-	-
<b>11</b>	<b>Total comprehensive income for the period (7+9)</b>	<b>60664</b>	<b>55888</b>	<b>52111</b>	<b>116552</b>	<b>101321</b>	<b>198469</b>
<b>12</b>	Total comprehensive income for the period attributable to:						
	Shareholders of the Company	60664	55888	52111	116552	101321	198469
	Non-Controlling Interest	-	-	-	-	-	-
<b>13</b>	Paid-up Equity Share Capital (Face Value: Rs.2/- per share)	5309	5309	5309	5309	5309	5309
<b>14</b>	Other equity excluding revaluation reserve						924152
<b>15</b>	<b>Earnings per Share of Rs. 2/- each (not annualized)</b>						
	a) Basic (Rs.)	22.84	20.99	19.57	43.83	38.11	74.75
	b) Diluted (Rs.)	22.84	20.99	19.57	43.83	38.11	74.75



**DIVI'S LABORATORIES LIMITED**

**STATEMENT OF CONSOLIDATED UNAUDITED ASSETS AND LIABILITIES AS AT 30<sup>TH</sup> SEPTEMBER 2021  
(Rs. in lakhs)**

S. No.	Particulars	As At	
		30.09.2021	31.03.2021
		(Unaudited)	(Audited)
<b>A</b>	<b>ASSETS</b>		
<b>1</b>	<b>Non-current assets</b>		
	Property, plant and equipment	410737	369466
	Right of use assets	384	426
	Capital work-in-progress	44023	71062
	Intangible assets	677	495
	Financial assets		
	a) Investments	1	1
	b) Other financial assets	5283	5678
	Income tax assets(net)	6151	6860
	Deferred tax asset	1300	323
	Other non-current assets	7410	5625
<b>2</b>	<b>Sub-total: Non-current assets</b>	<b>475966</b>	<b>459936</b>
	<b>Current assets</b>		
	Inventories	267635	214523
	Financial assets		
	a) Trade receivables	185226	167652
	b) Cash and cash equivalents	176279	203032
	c) Bank balances other than (b) above	11697	12571
	d) Other financial assets	822	947
	Income tax asset(net)	3427	3427
	Other current assets	22878	15319
	<b>Sub-total: Current assets</b>	<b>667964</b>	<b>617471</b>
	<b>TOTAL ASSETS</b>	<b>1143930</b>	<b>1077407</b>
<b>B</b>	<b>EQUITY AND LIABILITIES</b>		
<b>1</b>	<b>Equity:</b>		
	Share Capital	5309	5309
	Other Equity	987610	924152
	<b>Sub-total: Equity</b>	<b>992919</b>	<b>929461</b>
<b>2</b>	<b>Liabilities:</b>		
	<b>Non-current liabilities</b>		
	Financial liabilities		
	a) Lease Liabilities	329	369
	Provisions	3062	2525
	Deferred tax liabilities (net)	38048	33806
	<b>Sub-total: Non-current liabilities</b>	<b>41439</b>	<b>36700</b>
<b>3</b>	<b>Current Liabilities</b>		
	Financial liabilities		
	a) Borrowings	7	35
	b) Lease liabilities	81	79
	c) Trade payables		
	Dues to micro and small enterprises	1176	3248
	Dues to creditors other than micro and small enterprises	81996	73072
	d) Other financial liabilities	6004	8042
	Other current liabilities	18322	25921
	Current tax liabilities (net)	1735	598
	Provisions	251	251
	<b>Sub-total: Current liabilities</b>	<b>109572</b>	<b>111246</b>
	<b>Total Liabilities</b>	<b>151011</b>	<b>147946</b>
	<b>TOTAL EQUITY AND LIABILITIES</b>	<b>1143930</b>	<b>1077407</b>





**DIVI'S LABORATORIES LIMITED**

**STATEMENT OF CONSOLIDATED UNAUDITED CASH FLOWS FOR THE HALF YEAR ENDED 30<sup>TH</sup> SEPTEMBER 2021**

**(Rs. in lakhs)**

Particulars	30.09.2021 (Unaudited)	30.09.2020 (Unaudited)	31.03.2021 (Audited)
<b>A. Cash flow from operating activities</b>			
Profit before tax	157410	135447	266604
Adjustments for:			
Depreciation and amortisation expense	15061	11733	25559
Unrealised foreign exchange loss/ (gain)	(205)	527	(1328)
Exchange Gain /(Loss) on translation of foreign operations	124	238	22
Interest income from financial assets at amortized cost	(3347)	(2274)	(5724)
Net gain on redemption /disposal of investments	-	(265)	(265)
Provision for doubtful debts / (written back) [including write-off]	(169)	(35)	(11)
Finance costs	49	21	87
Loss on disposal / discard of assets	136	(11)	596
Government grants	(4)	(3)	(7)
	<b>169055</b>	<b>145378</b>	<b>285533</b>
<b>Change in operating assets and liabilities</b>			
(Increase) /Decrease in trade receivables	(18023)	(16531)	(26540)
(Increase) /Decrease in inventories	(53112)	16449	(28137)
Increase /(Decrease) in trade payables	7057	(4877)	17480
(Increase) /Decrease in current Loans	-	-	9
(Increase) /Decrease in other non-current assets	(123)	20	(232)
(Increase) /Decrease in non-current financial assets	395	(416)	(2146)
(Increase) /Decrease in other current financial assets	125	(393)	(558)
(Increase) /Decrease in other current assets	(7559)	4707	7242
Increase /(Decrease) in long term employee benefit obligation	549	242	498
Increase /(Decrease) in short term employee benefit obligation	-	(76)	5
Increase/ (Decrease) in other financial liabilities	220	(2792)	(2901)
Increase /(Decrease) in other current liabilities	(6984)	(97)	8872
<b>Cash generated from operations</b>	<b>91600</b>	<b>141614</b>	<b>259125</b>
Income taxes paid including withholding tax and net of refunds	(35878)	(25852)	(64432)
<b>Net cash inflow from operating activities</b>	<b>55722</b>	<b>115762</b>	<b>194693</b>
<b>B. Cash flows from investing activities</b>			
Payments for property, plant and equipment	(33464)	(37432)	(91019)
Proceeds from sale of property, plant and equipment	-	14	15
Payments for purchase of Investments	-	-	(10000)
Proceeds out of sale of Investments	-	97400	107400
Interest received	3137	2460	5701
Proceeds from withdrawal of deposits	1471	-	6810
Investment in deposits	(408)	(4460)	(11394)
<b>Net cash inflow / (outflow) from investing activities</b>	<b>(29264)</b>	<b>57982</b>	<b>7513</b>



**DIVI'S LABORATORIES LIMITED**

**STATEMENT OF CONSOLIDATED UNAUDITED CASH FLOWS FOR THE HALF YEAR ENDED 30<sup>TH</sup> SEPTEMBER 2021**

**(Rs. in lakhs)**

Particulars	30.09.2021 (Unaudited)	30.09.2020 (Unaudited)	31.03.2021 (Audited)
<b>C. Cash flows from financing activities</b>			
Proceeds/ (Repayment) of working capital loans (net)	(28)	(3340)	(3328)
Finance costs	(49)	(21)	(87)
Principal element of lease payments	(40)	(36)	(74)
Dividend paid to company's shareholders	(53094)	-	-
<b>Net cash inflow / (outflow) from financing activities</b>	<b>(53211)</b>	<b>(3397)</b>	<b>(3489)</b>
<b>Net increase /(decrease) in cash and cash equivalents (A+B+C)</b>	<b>(26753)</b>	<b>170347</b>	<b>198717</b>
Cash and cash equivalents at the beginning of the financial year	203032	4315	4315
<b>Cash and cash equivalents at end of the year/period</b>	<b>176279</b>	<b>174662</b>	<b>203032</b>

**NOTES:**

- The above Statement of consolidated unaudited financial results for the quarter and half year ended 30<sup>th</sup> September 2021, Statement of consolidated unaudited assets and liabilities as at 30<sup>th</sup> September, 2021 and Statement of consolidated unaudited cash flows for the half year ended 30<sup>th</sup> September, 2021 ('Consolidated Statements') are prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under section 133 of the Companies Act 2013 read with the relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. The same were, as reviewed by the Audit Committee, considered and approved by the Board of Directors at its meeting held on 6<sup>th</sup> November, 2021. The same also were subjected to "limited review" by the Auditors of the Company and their report contains no qualification.
- The consolidated unaudited results include the financial results of Divi's Laboratories Limited and its two subsidiaries Divis Laboratories (USA) Inc. and Divi's Laboratories Europe AG (Referred as the "Group").
- The group is engaged in the manufacture of Active Pharmaceutical ingredients, intermediates, and nutraceutical ingredients and the same constitutes single reportable business segment as per Ind AS 108.
- The Group does not have any discontinued operations and the Profit for the period represents the Profits from continuing operations only.
- The Group has not experienced any significant impact on its operations, supply chain and recoverability of carrying amounts of financial and non-financial assets due to COVID 19 pandemic. As the pandemic continues to evolve, the Group will continue to closely monitor for any material changes to future economic conditions.
- Forex gain included in Other Income and Loss included in Other Expenses for the respective periods is as given below:

Rs. in lakhs

	Quarter ended			Half Year ended		Year ended
	30.09.2021	30.06.2021	30.09.2020	30.09.2021	30.09.2020	31.03.2021
<b>Forex gain/(loss)</b>	<b>(712)</b>	1964	(1563)	<b>1252</b>	(1082)	(438)

- Figures for the previous year/period have been reclassified/ regrouped wherever necessary to conform to current period's classification.

For Divi's Laboratories Limited

Dr. Murali K. Divi  
Managing Director

Place: Hyderabad

Date: 6<sup>th</sup> November, 2021



# Price Waterhouse Chartered Accountants LLP

## Review Report

To

The Board of Directors  
M/s. Divi's Laboratories Limited  
Divis Towers, 1-72/23(P)/303,  
Cyber hills, Gachibowli,  
Hyderabad, 500032

1. We have reviewed the consolidated unaudited financial results of Divi's Laboratories Limited (the "Parent"), its subsidiaries (the parent and its subsidiaries hereinafter referred to as the "Group"), [(refer Note 2 on the Consolidated Statement)] for the quarter ended September 30, 2021 and the year to date results for the period April 01, 2021 to September 30, 2021 which are included in the accompanying "Statement of Consolidated Unaudited financial results for the quarter and half year ended September 30, 2021", the "Statement of Consolidated Unaudited Assets and Liabilities as on September 30, 2021" and the "Statement of Consolidated Unaudited Cash Flows for the half-year ended September 30, 2021" (the "Consolidated Statement"). The Consolidated Statement is being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations"), which has been stamped by us for identification purposes.
2. This Consolidated Statement, which is the responsibility of the Parent's Management and has been approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Consolidated Statement based on our review.
3. We conducted our review of the Consolidated Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Consolidated Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Consolidated Statement includes the results of the following subsidiaries:
  - a. Divi's Laboratories (USA) Inc.
  - b. Divi's Laboratories Europe AG

Price Waterhouse Chartered Accountants LLP, Unit - 2B, 8th Floor, Octave Block, Block E1, Parcel - 4, Salarpuri Sattva Knowledge City, Raidurg, Hyderabad, Telangana - 500081  
T: +91 (40) 4424 6000, F: +91 (40) 4424 6300

Registered office and Head office: Sucheta Bhawan, 11A Vishnu Digambar Marg, New Delhi 110 002

Price Waterhouse (a Partnership Firm) converted into Price Waterhouse Chartered Accountants LLP (a Limited Liability Partnership with LLP identity no: LLPIN AAC-5001) with effect from July 25, 2014. Post its conversion to Price Waterhouse Chartered Accountants LLP, its ICAI registration number is 012754N/N500016 (ICAI registration number before conversion was 012754N)



## Price Waterhouse Chartered Accountants LLP

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Consolidated Statement has not been prepared in all material respects in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
  
6. The consolidated unaudited financial results include the interim financial information/interim financial results of 2 subsidiaries which have not been reviewed by their auditors, whose interim financial results reflect total assets of Rs.36,198 lakhs and net assets of Rs.6,186 lakhs as at September 30, 2021 and total revenue of Rs.14,882 lakhs and Rs.25,825 lakhs, total net profit after tax of Rs. 527 lakhs and Rs. 1,293 lakhs and total comprehensive income of Rs.505 lakhs and Rs.1,362 lakhs for the quarter ended September 30, 2021 and for the period from April 01, 2021 to September 30, 2021, respectively, and cash outflows (net) of Rs. 186 lakhs for the period from April 01, 2021 to September 30, 2021, as considered in the consolidated unaudited financial results. According to the information and explanations given to us by the Management, these interim financial information/interim financial results are not material to the Group.

Our conclusion on the Consolidated Statement is not modified in respect of the above matter.

For Price Waterhouse Chartered Accountants LLP  
Firm Registration Number: 012754N/N500016



Sunit Kumar Basu  
Partner

Membership Number 55000

UDIN: 210 55000 AAAA KW 9332

Place: Hyderabad

Date: November 06, 2021

## **DIVI'S LABORATORIES LIMITED**

**CIN No.L24110TG1990PLC011854**  
**1-72/23(P)/DIVIS/303, Cyber Hills, Gachibowli**  
**Hyderabad – 500 032 Telangana, India**  
**Phone: 91-40-23786300 email: cs@divislabs.com**

**Press Release dated 6<sup>th</sup> November 2021**

**Divi's Labs earns a PAT of ₹ 606 crores for Q2 of FY22 on Consolidated Basis**

### **Consolidated Results**

Divi's Laboratories has earned a consolidated total income of ₹ 2007 crores for quarter ended 30<sup>th</sup> September 2021 as against a consolidated total income of ₹ 1763 crores in the corresponding quarter of the previous year.

Profit before Tax (PBT) for the quarter amounted to ₹ 760 crores as against a PBT of ₹ 693 crores for the corresponding quarter of the last year.

Profit after Tax (PAT) for the quarter grew by 17% to ₹ 606 crores as against a PAT of ₹ 520 crores for the corresponding quarter of the last year.

For the current quarter, we have a forex loss of ₹ 7 crores as against a loss of ₹ 16 crores during the corresponding quarter of last year.

For the half-year ended 30<sup>th</sup> September 2021, the company earned a consolidated total income of ₹ 3996 crores as against a consolidated total income of ₹ 3506 crores during the previous half-year. PAT for the current half-year came to ₹ 1164 crores as against ₹ 1012 crores for the previous half-year. For the current half-year, we had a forex gain of ₹ 13 crores as against a loss of ₹ 11 crores during the corresponding period last year.



## Standalone Results

On a standalone basis, the company's earnings are as given below:

₹ in crores

Particulars	For the Quarter ended		For the half year ended	
	<b>30-09-21</b>	30-09-20	<b>30-09-21</b>	30-09-20
Total Income	<b>1987</b>	1727	<b>3966</b>	3450
PBT	<b>760</b>	685	<b>1574</b>	1346
PAT	<b>606</b>	513	<b>1158</b>	1006

## Forex Gain/(loss)

Particulars of forex gain/(loss) for the period are given below:

₹ in crores

Particulars	For the Quarter ended		For the period ended	
	<b>30-09-21</b>	30-09-20	<b>30-09-21</b>	30-09-20
Forex gain/(loss)	<b>(7)</b>	(12)	<b>12</b>	(7)

The company continues to have near normal operations during the quarter complying to all Covid-19 protocols.